GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups
pharmafile | November 13, 2019 | News story | Research and Development | GSK, Nucala, pharma
GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary endpoint in the treatment of the rare disease hypereosinophilic syndrome (HES).
In the trial, 50% fewer participants were shown to experience a flare-up of HES-related symptoms when treated with Nucala alongside standard of care as opposed to placebo plus standard of care over 32 weeks of treatment.
Additionally, Nucala patients exhibited a 66% lower risk of first HES flare-up compared to placebo, as well as a 66% reduction in the annualised rate of flare-ups. On the back of the trial results, GSK asserted that Nucala was the first therapy to demonstrably reduce HES-related flare-ups. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, remarked: “Mepolizumab has the potential to change the treatment landscape for patients with HES which is a complex and debilitating disease with limited therapeutic options today.”
Dr Gerald Gleich, an allergist, immunologist and HES expert at the University of Utah, also commented: “Mepolizumab is thought to work by reducing blood eosinophil levels and evidence suggests it has potential as a targeted treatment option for a range of inflammatory diseases driven by raised eosinophils. These data are very promising and should provide hope for patients affected by this rare, life-threatening condition caused by eosinophilic inflammation.”
GSK confirmed it would be submitting these data to regulatory bodies around the world in a bit to secure the first HES-related approvals for Nucala.
Matt Fellows
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
